Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | R-9-033 |
Topic: | PET and PET/CT Scanning for Oncologic Indications |
Section: | Radiation Therapy & Nuclear Medicine |
Effective Date: | January 1, 2017 |
Issue Date: | January 2, 2017 |
Last Reviewed: | August 2016 |
|
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
Initial Anti-tumor Treatment Strategy
PET imaging using the radiopharmaceutical diagnostic imaging agent fluorodeoxyglucose F-18 (FDG) may be considered medically necessary to determine the appropriate initial anti-tumor treatment strategy for patients with the following types of cancers:
PET imaging using the radiopharmaceutical diagnostic imaging agent sodium fluoride-18 (NaF-18) is recognized as useful for imaging areas of altered osteogenic activity in bone. The treating physician may determine that the NaF-18 PET study is needed to determine the initial antitumor treatment strategy, or to guide subsequent antitumor treatment strategy after the completion of initial treatment. In these situations, it will be necessary for the provider to submit medical records and/or additional documentation to determine coverage in this situation as described above.
One (1) PET study may be considered medically necessary for patients with solid tumors that are biopsy proven or strongly suspected based on other diagnostic testing, and the patient's treating physician determines that a PET study is needed to determine the location and/or extent of the tumor for therapeutic purposes related to the initial treatment strategy, such as determining:
All policy statements apply to both positron emission tomography (PET) scans and PET/computed tomography (CT) scans, ie, PET scans with or without PET/CT fusion.
For the clinical situations indicated that may be considered medically necessary, this is with the assumption that the results of the PET scan will influence treatment decisions.
If the results will not influence treatment decisions, these situations would be considered not medically necessary
Bone Cancer
PET scanning may be considered medically necessary in the staging of Ewing sarcoma and osteosarcoma.
PET scanning is considered experimental/investigational in the staging of chondrosarcoma.
Brain Cancer
PET scanning may be considered medically necessary for diagnosing and staging of brain cancer:
Breast Cancer
Pet scanning may be considered medically necessary in the staging and restaging of breast cancer for the following application:
Pet scanning is considered experimental/investigational in the evaluation of breast cancer for all other applications, including but not limited to the following:
Cervical Cancer
PET scans may be considered medically necessary in the initial staging of patients with locally advanced cervical cancer.
PET scans may be considered medically necessary in the evaluation of known or suspected recurrence.
Colorectal Cancer
PET scanning may be considered medically necessary as a technique for:
PET scanning is considered experimental/investigational as:
Esophageal Cancer
PET scanning may be considered medically necessary for the following:
PET scanning is considered experimental/investigational in other aspects of the evaluation of esophageal cancer, including but not limited to the following applications:
Gastric Cancer
PET scanning may be considered medically necessary for the following:
Gastrointestinal Stromal Tumors
PET scanning may be considered medically necessary in the staging and evaluation of the response to imatinib mesylate in gastrointestinal stromal tumors (GIST).
Head and Neck Cancer:
PET scanning may be considered medically necessary in:
Lung Cancer
PET scanning may be considered medically necessary for any of the following applications:
PET scanning is considered experimental/investigational in staging of small cell lung cancer.
Lymphoma, Including Hodgkin’s Disease
PET scanning may be considered medically necessary as a technique for staging lymphoma either during initial staging or for restaging at follow-up.
Malignant Pleural Mesothelioma
PET scanning may be considered medically necessary for the staging and restaging of malignant mesothelioma.
Melanoma
PET scanning may be considered medically necessary as a technique for assessing extranodal spread of malignant melanoma at initial staging or at restaging during follow-up treatment.
PET scanning is considered experimental/investigational as a technique to detect regional lymph node metastases in
patients with clinically localized melanoma who are candidates to undergo sentinel node biopsy.
Multiple Myeloma and Plasmacytomas:
PET scanning may be considered medically necessary for evaluating suspected plasmacytomas (staging) in:
Ovarian Cancer
PET scanning may be considered medically necessary in the evaluation of patients with signs and/or symptoms of suspected ovarian cancer recurrence (restaging) when standard imaging, including CT scan, is inconclusive.
PET scanning is considered experimental/investigational in the initial evaluation of known or suspected ovarian cancer in all situations.
Pancreatic Cancer
PET may be considered medically necessary in the initial diagnosis and staging of pancreatic cancer when other imaging and biopsy are inconclusive.
PET scanning is considered experimental/investigational as a technique to evaluate other aspects of pancreatic cancer.
Sarcomas
PET scans for Ewing’s sarcoma and osteogenic sarcoma for both initial and subsequent anti-tumor treatment strategy. Ewing's sarcoma or osteogenic sarcoma may be considered medically necessary:
Small Cell Lung
PET scanning may be considered medically necessary in:
Soft Tissue Sarcoma
PET scanning is considered experimental/investigational in evaluation of soft tissue sarcoma, including but not limited to the following applications:
Testicular
PET may be medically necessary in evaluation of residual mass following chemotherapy of stage IIB and III seminomas in patients with a CT documented residual mass after chemotherapy treatment. (The PET scan should be completed not sooner than 6 weeks following chemotherapy)
Except as noted above for above for seminoma, PET scanning is considered experimental/investigational in evaluation of testicular cancer, including but not limited to the following applications:
Thymic Tumors
PET scanning may be considered medically necessary for the diagnosis and staging of thymic tumors.
Thyroid
PET scanning may be considered medically necessary in the restaging of patients with differentiated thyroid cancer when thyroglobulin (Tg) levels are elevated and have a negative I-131 whole body scan.
PET scanning is considered experimental/investigational in the evaluation of known or suspected differentiated or poorly differentiated thyroid cancer in all other situations.
Unknown Primary
PET scanning may be considered medically necessary in patients with an unknown primary who meet ALL of the following criteria:
PET scanning is considered experimental/investigational for other indications in patients with an unknown primary, including, but not limited to the following:
Other Oncologic Applications
Other oncologic applications of PET scanning, including but not limited to the following, are considered experimental/investigational:
A subsequent PET study may be considered medically necessary for tumor types other than those listed above when the patient’s treating physician determines that the PET study is needed to determine if there is a need to develop a treatment plan for subsequent anti-tumor treatment.
It will be necessary for the provider to submit medical records and/or additional documentation to determine coverage in this situation. For example, the documentation should indication whether the prospective PET scan will lead to:
Surveillance
Surveillance PET scanning is a study performed after the completion of treatment, in the absence of signs or symptoms of cancer recurrence or progression, for the purpose of detecting recurrence or progression, or predicting outcome. Surveillance has also been called “tertiary prevention.”
PET performed for surveillance is considered not medically necessary for the following reasons:
NOTE:
A scan is considered surveillance if performed more than 6 months after completion of cancer therapy (12 months for lymphoma) in patients without objective signs or symptoms suggestive of cancer recurrence.
PET Scans Using a Coincidence Detection System
The use of a non-dedicated PET scanner, also called a coincidence detection system will be denied as non-covered and therefore no payment can be made because it was performed on equipment that does not provide images that meet clinically accepted standards of quality.
Modifiers PI and PS
Modifiers –PI and –PS are to be used to identify those PET studies performed for initial (PI) or subsequent (PS) anti-tumor treatment strategy.
PI - Positron Emission Tomography (PET) or PET/Computed Tomography (CT) to indicate the initial treatment strategy of tumors that are biopsy proven or strongly suspected of being cancerous based on other diagnostic testing.
PS - Positron Emission Tomography (PET) or PET/Computed Tomography (CT) to indicate the subsequent treatment strategy of cancerous tumors when the patient’s treating physician determines that the PET study is needed to plan subsequent anti-tumor strategy.
For information on PET imaging for nonmalignant applications see Medical Policy Bulletin R-8. |
Place of Service: Outpatient |
Experimental/Investigational (E/I) services are not covered regardless of place of service.
The use of PET and PET/CT scanning for oncologic indications is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will not be considered medically necessary. A network provider cannot bill the member for the denied service unless: (a) the provider has given advance written notice, informing the member that the service may be deemed not medically necessary; (b) the member is provided with an estimate of the cost; and (c) the member agrees in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
A network provider can bill the member for the non-covered service.
Links |